Does Amiodarone Cause Bradycardia?
Yes, amiodarone definitively causes bradycardia and conduction disturbances, occurring in approximately 9-16% of patients depending on the route of administration and patient characteristics. This is a well-established adverse effect documented in both FDA labeling and clinical guidelines 1, 2.
Mechanism and Incidence
Amiodarone causes bradycardia through its class III antiarrhythmic effects (potassium channel blockade) and class I effects (sodium channel blockade), which slow conduction through the sinoatrial and atrioventricular nodes. The incidence varies by administration route:
- Intravenous amiodarone: Causes bradycardia or heart block in 4.9% of patients and hypotension in 16% 1
- Oral amiodarone: Bradycardia or conduction disturbance is the most common adverse effect, occurring in 9.5% of patients in real-world practice 3
- During loading phase: Sinus bradycardia occurs in 32% of patients during saturation dosing, dropping to 11.2% during maintenance therapy 4
High-Risk Populations
The risk of symptomatic bradycardia requiring pacemaker insertion is substantially elevated in specific patient groups:
Pre-existing Conduction Disease
Patients with baseline conduction abnormalities face a 24% risk of developing symptomatic bradycardia on amiodarone 5. In contrast, patients without pre-existing conduction disorders had zero cases of symptomatic bradycardia in the same study—a statistically significant difference (p < 0.0005).
Elderly Patients with Atrial Fibrillation
Amiodarone doubles the risk of bradyarrhythmia requiring permanent pacemaker insertion in elderly patients (≥65 years) with atrial fibrillation and prior myocardial infarction (OR: 2.14,95% CI: 1.30-3.54) 6. Elderly women face an even higher risk (OR: 3.86) compared to elderly men (OR: 1.52) 6.
Post-Heart Transplant Patients
Sinus bradycardia from prior amiodarone use is a recognized contributor to post-transplant conduction abnormalities 7.
Contraindications and Precautions
Amiodarone therapy is absolutely contraindicated in patients with second- or third-degree heart block who do not have a pacemaker 1. The FDA labeling reinforces that intravenous amiodarone should not be used in patients with bradycardia or heart block without a pacemaker 1.
Required Monitoring
Guidelines mandate close surveillance of heart rate, especially during the first week of treatment 1. The monitoring protocol includes:
- Baseline complete history and physical examination with attention to conduction abnormalities
- Close heart rate surveillance during outpatient loading
- History and physical examination every six months directed at detecting bradycardia
Drug Interactions Potentiating Bradycardia
Digoxin is the only other medication independently associated with increased pacemaker insertion risk (OR: 1.78) when used with amiodarone 6. Amiodarone predictably doubles digoxin levels by inhibiting renal tubular secretion, necessitating a 50% reduction in digoxin dosage when starting amiodarone 1.
Recent evidence shows that concurrent use of amiodarone with beta-blockers increases bradycardia-related complications (2.7% vs 1.5%, OR: 1.83, p = 0.038), though this combination may reduce rhythm-related rehospitalizations 8.
Clinical Management
When bradycardia occurs during amiodarone therapy:
- For IV administration: Discontinue infusion or reduce the infusion rate immediately 1
- For oral therapy: Bradycardia typically improves after lowering the amiodarone dose and rarely requires cessation or pacing 4
- Duration of treatment is the only independent predictor of adverse effects (OR: 1.21 per year), not the daily dose 3
Common Pitfall
Atropine is ineffective for treating amiodarone-induced bradycardia in post-heart transplant patients due to cardiac denervation 7. In these cases, aminophylline or theophylline are reasonable alternatives.
Overdose Considerations
Amiodarone overdose can cause severe bradycardia and AV block requiring temporary pacing 2. The drug is not dialyzable, and effects may persist for weeks after discontinuation due to its extremely long half-life (20-47 days in elderly patients) 2, 9.